3 Biotech Stocks That Made Early Shareholders Millionaires
The biotechnology industry has created a staggering amount of wealth for investors over the past 40 years. The blistering pace of innovation, coupled with the rapid growth of scores of chronic diseases like asthma, arthritis, diabetes, cancer, and heart disease, have acted in concert to make biotech one of the fastest growing industries in the world during this period.
Several biotech stocks have thus gone on to produce million-dollar paydays for early bird investors. In fact, the brave souls who got in on the ground floor in some of the industry's biggest names typically only had to shell out fairly modest amounts of capital (less than $10,000) to realize a million-dollar gain.
Which biotech stocks have been the most potent wealth generators for investors during the industry's formative years? Not surprisingly, the big biotechs Amgen (NASDAQ: AMGN), Biogen (NASDAQ: BIIB), and Gilead Sciences (NASDAQ: GILD) have each delivered million-dollar paydays for their original shareholders. Here's a rundown on how much you would have had to invest in the initial public offerings (IPO) of these three biotech titans to score a millionaire gain at today's levels.
Source Fool.com
